Eli Lilly and Co. shares surged 13% after announcing positive phase 3 results for orforglipron, a groundbreaking diabetes and weight loss pill. CEO David Ricks praised its safety, ...
Eli Lilly and Co. shares surged 13% after announcing positive phase 3 results for its orforglipron diabetes and weight-loss drug, a potential game-changer in treatment options.
Eli Lilly and Co. shares surged 13% after announcing positive phase 3 results for orforglipron, a groundbreaking weight-loss and diabetes pill. The drug, the first of its kind to c...
Eli Lilly plans to transform India's pharmaceutical market with innovative treatments for diabetes and obesity, leveraging AI and global expertise to address the country's health c...
Eli Lilly and Company forecasts a significant revenue increase to $58-61 billion by 2025, driven by strong sales of its diabetes and obesity treatments, Mounjaro and Zepbound. CEO ...
